• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ispire Technology Inc. Reports Fiscal Third Quarter 2024 Financial Results

    5/14/24 5:35:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ISPR alert in real time by email

    Total Revenue Increased 24% year-over-year to $30.0 Million

    Gross Profit Increased 35% year-over-year to $6.1 Million

    North American Cannabis Vaping Hardware Revenue Increased 57% year-over-year to $11.9 Million 

    Closed $12.3 million public offering

    LOS ANGELES, May 14, 2024 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire" or the "Company"), an innovator in vaping technology and precision dosing, today reported results for the fiscal third quarter, which ended March 31, 2024 and filed its quarterly report on Form 10-Q on May 14, 2024.

    Fiscal Third Quarter 2024 Financial Results

    • Revenue increased 24% to $30.0 million as compared to $24.1 million in the same period of 2023. Tobacco vaping products contributed $18.1 million and cannabis vaping products contributed $11.9 million to revenue during the fiscal third quarter 2024;
    • Gross profit increased 35% to $6.1 million for the three-month period ended March 31, 2024, compared to $4.5 million in the third quarter of fiscal 2023.  Gross profit for the nine-month period ended March 31, 2024, was $19.2 million, compared to $14.3 million for the same period in fiscal 2023.
    • Gross margin increased to 20.4% as compared to 18.7% in the same period of 2023;
    • Total operating expenses increased 63.7% to $11.8 million as compared to $7.2 million in the same period of 2023; and
    • Net loss of $5.9 million as compared to net loss of $2.3 million in the same period of 2023.

    Michael Wang, Co-Chief Executive Officer of Ispire commented, "the third quarter was important for Ispire as it demonstrated our continued ability to add new strategic partners and expand within existing market sectors as we execute on our mission to be an innovator and a leader in our markets. During the quarter, we entered into a joint venture with Berify and Chemular, and, subsequent to the end of the quarter, announced a partnership with a subsidiary of Acreage Holdings, Inc. (OTC:ACRGF). These partnerships will allow us to continue to expand our market share as we offer our cutting-edge products and technology globally."

    "Also during the quarter, we successfully closed on a $12.3 million public offering.  This additional capital will allow us to help fund our joint venture with our partners and also ramp up our operations at our Malaysian manufacturing facility. This facility will play an important part in our operational and financial performance as it further streamlines our supply chain which will lead to improved gross margins and profitability," concluded Wang.

    Daniel Machock, Chief Financial Officer of Ispire, stated, "our third quarter results reflect Ispire's ability to capitalize on areas of strength and to quickly pivot to meet our expectations for our markets.  We successfully demonstrated this ability in the third quarter, shifting our focus to increasing profitability due to the anticipated seasonal impact of Chinese New Year on our manufacturing partners.  This ability allowed us to continue to invest in research and innovation, while expanding in our existing markets and ensuring that we were well-positioned to enter new markets where we believe there is significant market opportunity."

    Financial Results for the Three and Nine-Month Periods Ended March 31, 2024

    Revenue increased 24% to $30.0 million for the fiscal third quarter ended March 31, 2024, compared to $24.1 million in the third quarter of fiscal 2023. The increase in the third quarter of fiscal 2024, was primarily attributable to an increase in North American cannabis vaping hardware sales which increased 57% year-over-year from $7.6 million to $11.9 million. 

    For the nine-month period ended March 31, 2024, Ispire reported revenue of $114.6 million compared to $83.0 million during the same period last year, an increase of 38%. The increase in revenue was primarily attributable to an increase in North American cannabis vaping hardware sales which increased 108% from $23.4 million for the first nine-months of fiscal 2023 to $48.8 million for the first nine-months of fiscal 2024. 

    Gross profit increased by 35% to $6.1 million for the three-month period ended March 31, 2024, compared to $4.5 million in the third quarter of fiscal 2023. Gross profit for the nine-month period ended March 31, 2024, was $19.2 million compared to $14.3 million for the same period in fiscal 2023. 

    Gross margin for the three months ended March 31, 2024, was 20.4% compared to 18.7% for the same period in fiscal 2023. For the nine-month period ended March 31, 2024, gross margin was 16.8%, compared to 17.2% during the same period in the prior fiscal year. 

    Total operating expenses increased by 64% to $11.8 million for the third quarter in fiscal 2024, compared to $7.2 million for the same period of fiscal 2023. This increase was primarily due to marketing expenses and working capital related to maintaining our manufacturing plant in Malaysia and increased professional fees for expenses incurred as a public company. Total operating expenses for the nine-months ended March 31, 2024, were $29.8 million as compared to $17.9 million in the same period in fiscal 2023. 

    Net loss was $5.9 million or $0.11 per share, for the third quarter of fiscal 2024, compared to a net loss of $2.3 million, or $0.05 per share for the third quarter of fiscal 2023. For the first nine-months of fiscal 2024, net loss was approximately $11.3 million or $0.21 per share, compared to a net loss of approximately $4.5 million, or $0.09 per share for the first nine-months of fiscal 2023. 

    As of March 31, 2024, Ispire had approximately $39.5 million in cash and cash equivalents. As of March 31, 2024, and June 30, 2023, we had working capital of $28.9 million and $28.8 million respectively.

     

    Non-GAAP net loss for the nine months ended March 31, 2024 and 2023























     Nine months ended March 31,











    2024



    2023

















    Net loss







    $

    (11,346,690)

    $

    (4,512,513)

















    add

    Stock-based compensation expenses



    4,691,872



    -

    add

    Credit loss expenses





    3,318,772



    2,330,835

    add

    Patent expenses, net off capitalization



    380,768



    1,534,899

















    Non-GAAP net loss





    $

    (2,955,278)

    $

    (2,977,614)

















     

    Conference Call

    The Company will conduct a conference call at 8:00 am Eastern Time on Wednesday May 15, 2024, to discuss the results. Ispire management will host the conference call, followed by a question-and-answer period.

    Please call the conference call dial-in 5-10 minutes prior to the start time and ask for the "Ispire Technology Call." An operator will register your name and organization.

    • Date: Wednesday, May 15, 2024
    • Time: 8:00 am ET
    • Dial-In Numbers: United States 877-451-6152 or International +1 201-389-0879

    This conference call will be broadcast live on the Internet and can be accessed by all interested parties at https://viavid.webcasts.com/starthere.jsp?ei=1669249&tp_key=6a1ed4d261.

    Please access the link at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software.

    A playback will be available through 11:00 am ET on May 15, 2024, to May 29, 2024. To listen, please dial 844-512-2921 or +1 412-317-6671. Use the passcode 13746419 to access the replay.

    About Ispire Technology Inc.

    Ispire is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The Company's operating subsidiaries own or license more than 200 patents received or filed globally. Ispire's tobacco products are marketed under the Aspire brand name and are sold worldwide (except in the U.S., People's Republic of China and Russia) primarily through its global distribution network. The Company's cannabis products are marketed under the Ispire brand name primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware only in the U.S., and it recently commenced its marketing activities in Canada and Europe. For more information, visit www.ispiretechnology.com or follow Ispire on  Instagram, LinkedIn, Facebook, Twitter and YouTube. Any information contained on, or that can be accessed through, the Company's website, any other website or any social media, is not a part of this press release.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Joint Venture may be successful in achieving its goals as currently contemplated, with different terms, or at all, the Joint Venture's ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices, the Company's ability to collect its accounts receivable in a timely manner, the Company's business strategies, the ability of the Company to market to the Ispire ONE™, Ispire ONE™'s success if meeting its goals, the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of their products on the markets; the Ispire ONE™ proving to be safe, and the risk and uncertainties described in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Cautionary Note on Forward-Looking Statements" and the additional risk described in Ispire's Annual Report on Form 10-K for the year ended June 30, 2023 and any subsequent filings which Ispire makes with the U.S. Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in the press release relate only to events or information as of the date on which the statements are made in the press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.



    For more information, kindly contact:

    IR Contacts:

    Investor Relations

    Sherry Zheng

    718-213-7386

    [email protected]

    KCSA Strategic Communications

    Phil Carlson

    212-896-1233

    [email protected]

    PR Contact:

    Ellen Mellody

    570-209-2947

    [email protected]

     

    ISPIRE TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS







    June 30,













    2023

    (Note 2)





    March 31,

    2024



    Assets













    Current assets:













    Cash



    $

    40,300,573





    $

    39,453,727



    Accounts receivable, net





    24,526,262







    47,732,178



    Inventories





    7,472,108







    9,813,782



    Prepaid expenses and other current assets





    3,378,617







    1,652,850



    Investment - other





    9,133,707







    -



    Total current assets





    84,811,267







    98,652,537



    Other assets:

















    Property, plant and equipment, net





    1,088,131







    2,166,563



    Intangible assets, net





    -







    968,033



    Rental deposit





    732,334







    725,979



    Right-of-use assets – operating leases





    4,061,617







    3,636,104



    Long term investment





    -







    2,000,000



    Total other assets





    5,882,082







    9,496,679



    Total assets



    $

    90,693,349





    $

    108,149,216



    Liabilities and stockholders' equity

















    Current liabilities

















    Accounts payable



    $

    1,274,391





    $

    3,667,581



    Accounts payable – related party





    51,698,588







    61,030,319



    Contract liabilities





    988,556







    1,327,371



    Accrued liabilities and other payables





    281,361







    2,441,849



    Due to a related party





    710,910







    -



    Income tax payable





    63,853







    -



    Operating lease liabilities – current portion





    944,525







    1,275,923



    Total current liabilities





    55,962,184







    69,743,043





















    Other liabilities:

















    Operating lease liabilities – net of current portion





    3,356,232







    2,730,574



    Total liabilities





    59,318,416







    72,473,617





















    Commitments and contingencies



































    Stockholders' equity:

















    Common stock, par value $0.0001 per share; 140,000,000 shares

    authorized; 54,222,420 and 56,329,396 shares issued and

    outstanding as of June 30, 2023 and March 31, 2024





    5,422







    5,633



    Preferred stock, par value $0.0001 per share, 10,000,000 shares

    authorized, no shares issued at June 30, 2023 and March 31,

    2024





    -







    -



    Additional paid-in capital





    25,685,475







    41,163,042



    Retained earnings (accumulated deficit)





    5,847,804







    (5,498,886)



    Accumulated other comprehensive (loss) income





    (163,768)







    5,810



    Total stockholders' equity





    31,374,933







    35,675,599



    Total liabilities and stockholders' equity



    $

    90,693,349





    $

    108,149,216



    See notes to unaudited condensed consolidated financial statements.

     

     

    ISPIRE TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND

    COMPREHENSIVE LOSS







    Three Months Ended

    March 31,





    Nine Months Ended

    March 31,







    2023





    2024





    2023





    2024



    Revenue



    $

    24,136,297





    $

    30,015,036





    $

    82,976,746





    $

    114,565,244





































    Cost of revenue





    19,616,098







    23,893,083







    68,699,245







    95,345,545





































    Gross profit





    4,520,199







    6,121,953







    14,277,501







    19,219,699





































    Operating expenses:

































    Sales and marketing expenses





    948,302







    1,754,760







    3,182,451







    4,174,386



    General and administrative expenses





    6,261,326







    10,047,116







    14,689,504







    25,587,145





































    Total operating expenses





    7,209,628







    11,801,876







    17,871,955







    29,761,531





































    Loss from operations





    (2,689,429)







    (5,679,923)







    (3,594,454)







    (10,541,832)





































    Other income (expense):

































    Interest income, net





    391







    27,296







    77,202







    298,161



    Exchange gain (loss), net





    660,760







    (53,904)







    183,178







    (19,387)



    Other income (expense), net





    (67,953)







    12,265







    (108,440)







    20,078





































    Total other income (expense), net





    593,198







    (14,343)







    151,940







    298,852





































    Loss before income taxes





    (2,096,231)







    (5,694,266)







    (3,442,514)







    (10,242,980)





































    Income taxes - current





    (237,992)







    (255,485)







    (1,069,999)







    (1,103,710)





































    Net loss



    $

    (2,334,223)





    $

    (5,949,751)





    $

    (4,512,513)





    $

    (11,346,690)





































    Other comprehensive loss

































    Foreign currency translation adjustments





    (157,704)







    10,788







    (15,274)







    169,578



    Comprehensive loss



    $

    (2,491,927)





    $

    (5,938,963)





    $

    (4,527,787)





    $

    (11,177,112)





































    Net loss per share

































    Basic and diluted



    $

    (0.05)





    $

    (0.11)





    $

    (0.09)





    $

    (0.21)





































    Weighted average shares outstanding:

































    Basic and diluted





    50,000,000







    54,347,729







    50,000,000







    54,287,624



    See notes to unaudited condensed consolidated financial statements.

     

     

    ISPIRE TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS







    Nine Months ended

    March 31,







    2023





    2024







    (Restated)









    Net loss



    $

    (4,512,513)





    $

    (11,346,690)



    Adjustments to reconcile net loss to net cash provided by (used in)

    operating activities:

















    Depreciation and amortization





    20,878







    138,546



    Credit loss expenses





    2,330,835







    3,318,772



    Stock-based compensation expenses





    -







    4,691,872



    Inventory impairment





    -







    168,585



    Changes in operating assets and liabilities:

















    Accounts receivable





    (9,428,024)







    (26,553,830)



    Inventories





    343,395







    (2,510,259)



    Prepaid expenses and other current assets





    143,682







    1,732,122



    Accounts payable and accounts payable – related party





    13,737,398







    11,904,642



    Contract liabilities





    (940,014)







    350,227



    Accrued liabilities and other payables





    273,565







    1,160,487



    Operating lease liabilities





    128,865







    (63,853)



    Income tax payable





    (481,113)







    131,253



    Net cash provided by (used in) operating activities





    1,616,954







    (16,878,126)





















    Cash flows from investing activities:

















    Purchase of property, plant and equipment





    (495,065)







    (1,205,716)



    Acquisition of intangible assets





    -







    (979,295)



    Purchase of short term investment





    (9,604,418)







    -



    Maturity of short term investment





    -







    9,133,707



    Acquisition of long term investment





    -







    (1,000,000)



    Net cash (used in) provided by investing activities





    (10,099,483)







    5,948,696





















    Cash flows from financing activities:

















    Payment made for dividends





    (3,384,678)







    -



    Advances from related parties





    1,934,855







    -



    Repayments of advances from a related party





    (40,512,691)







    (703,322)



    Proceeds from a secondary offering





    -







    12,300,000



    Costs of a secondary offering





    -







    (1,514,094)



    Net cash (used in) provided by financing activities





    (41,962,514)







    10,082,584





















    Net decrease in cash





    (50,445,043)







    (846,846)



    Cash - beginning of period





    74,480,651







    40,300,573



    Cash - end of period



    $

    24,035,608





    $

    39,453,727



    Supplemental non-cash investing and financing activities

















    Leased assets obtained in exchange for operating lease liabilities



    $

    4,882,220





    $

    495,739



    Unpaid long term investment in accrued liabilities and other payables



    $

    -





    $

    1,000,000



    Supplemental disclosures

















    Cash paid for income taxes



    $

    1,666,543





    $

    1,355,110



    Cash paid for interest



    $

    587





    $

    7,399



    See notes to unaudited condensed consolidated financial statements.

     

     

    Cision View original content:https://www.prnewswire.com/news-releases/ispire-technology-inc-reports-fiscal-third-quarter-2024-financial-results-302145048.html

    SOURCE Ispire Technology Inc.

    Get the next $ISPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISPR

    DatePrice TargetRatingAnalyst
    5/20/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $ISPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire-Backed IKE Tech Invited to Participate in FDA Roundtable on PMTA Submissions

    Invitation-Only Forum Underscores FDA Recognition of IKE Tech as a Key Stakeholder and Highlights the Strategic Role of Age-Gating Technology in the Future of ENDS Regulation and Compliance LOS ANGELES, Feb. 4, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced that IKE Tech LLC ("IKE Tech" or "IKE"), a joint venture that includes Ispire as a founding partner, has been invited by the U.S. Food and Drug Administration (FDA) to participate in its Roundtable Discussion with Small ENDS Manufacturers on Premarket Tobacco Product Application (PMTA) Submissions.

    2/4/26 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    $ISPR
    SEC Filings

    View All

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    2/6/26 4:30:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    11/6/25 4:31:10 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by Ispire Technology Inc.

    10-K - Ispire Technology Inc. (0001948455) (Filer)

    9/15/25 4:06:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CLO and Secretary Pryzbyla Steven P. sold $29,592 worth of shares (9,000 units at $3.29), decreasing direct ownership by 2% to 390,664 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    2/17/26 5:53:18 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Fargis John sold $14,625 worth of shares (7,500 units at $1.95), decreasing direct ownership by 16% to 39,099 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    11/24/25 4:30:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    CLO and Secretary Pryzbyla Steven P. sold $45,001 worth of shares (17,046 units at $2.64), decreasing direct ownership by 4% to 399,664 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    10/2/25 4:30:03 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Ispire Technology with a new price target

    ROTH MKM initiated coverage of Ispire Technology with a rating of Buy and set a new price target of $11.00

    5/20/24 7:18:59 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Financials

    Live finance-specific insights

    View All

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Second Quarter 2026 Earnings Conference Call

    LOS ANGELES, Feb. 3, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Friday, February 6, 2026, to discuss the Company's financial results for its fiscal second quarter ended December 31, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Friday, February 6, 2026Time: 8:00 am ETDial-In Number

    2/3/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal First Quarter 2026 Earnings Conference Call

    LOS ANGELES, Nov. 4, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, November 6, 2025, to discuss the Company's financial results for its fiscal first quarter ended September 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Thursday, November 6, 2025Time: 8:00 am ETDial-In Nu

    11/4/25 4:05:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ispire Technology Inc.

    SC 13G - Ispire Technology Inc. (0001948455) (Subject)

    7/12/24 5:00:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Leadership Updates

    Live Leadership Updates

    View All

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Ispire-Backed IKE Tech to Spotlight Breakthroughs in Vape Safety and Harm Reduction at World Vape Show Dubai

    President of Ike Tech and SVP of International Nicotine at Ispire, John Patterson, to Join Global Leaders on Industry Innovation Panel LOS ANGELES, June 16, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a global leader in vaporization technology and precision dosing, announced its joint venture IKE Tech LLC ("IKE Tech") will spotlight Ike Tech's blockchain based point of use age-gating and Smart-Tag authentication technologies at the World Vape Show Dubai, June 18–20, 2025. John Patterson, president of Ike Tech and senior vice president of International Nicotine at Ispire, will be featured on a high-level panel titled "Innovations in Consumer Safety

    6/16/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

    Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

    5/15/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care